Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRay GroupSHSE:688301 -2.07%95 EBITDA Margin % is 31.89% as of Jun. 2026, which is 8% below its 10-year median of 34.55. GuruFocus rates SHSE:688301 with a GF Score™ of 95/100 and a GF Value™ of ¥109.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, iRay Group ranks better than 90.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. iRay Group's EBITDA for the
three
months ended in Jun. 2026 was ¥314 Mil. iRay Group's Revenue for the
three
months ended in Jun. 2026 was ¥985 Mil. Therefore, iRay Group's EBITDA margin for the quarter that ended in Jun. 2026 was 31.89%.
iRay Group (SHSE:688301) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
iRay Group EBITDA Margin % Related Terms
iRay Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for iRay Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688301 vs ISRG, BDX, RMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, iRay Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRay Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRay Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where iRay Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRay Group (SHSE:688301) has a EBITDA Margin % of 31.89% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iRay Group and its competitors. This is near median its historical median of 34.55. Over the past decade, iRay Group's EBITDA Margin % has ranged from 18.11 to 50.04. According to the industry distribution chart, iRay Group ranks #76 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 9.3%.
Is iRay Group's EBITDA Margin % too high?
iRay Group's current EBITDA Margin % of 31.89% is near median its 10-year median of 34.55. Over the past 10 years, this metric has ranged from a low of 18.11 to a high of 50.04. The Medical Devices & Instruments industry median EBITDA Margin % is 7.98. iRay Group's value of 31.89% is 299.6% above this industry median. Based on the distribution chart, iRay Group ranks #76 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRay Group has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRay Group's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iRay Group ranks #76 out of 814 companies for EBITDA Margin %. This places iRay Group in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.98. iRay Group's value of 31.89% is 299.6% above this benchmark. Historically, iRay Group's own EBITDA Margin % has ranged from 18.11 to 50.04 over the past decade. While the company's 10-year median is 34.55 vs. the industry median of 7.98, iRay Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.98, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRay Group's current EBITDA Margin % of 31.89% is 299.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iRay Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRay Group's current EBITDA Margin % is 31.89%, which is near median its own 10-year median of 34.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRay Group stock overvalued right now?
Based on GuruFocus' analysis, iRay Group (SHSE:688301) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥109.99, compared to a current price of ¥88.54 — trading 19.5% below its estimated fair value. The current EBITDA Margin % is 31.89%, which is near median its 10-year median of 34.55 and 299.6% above the Medical Devices & Instruments industry median of 7.98. iRay Group's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For iRay Group (SHSE:688301), the current EBITDA Margin % is 31.89% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRay Group (SHSE:688301) Overvalued in 2026?
Based on GuruFocus' analysis, iRay Group stock appears to be undervalued.
The current stock price of ¥88.54 is trading 19.5% below its estimated GF Value™ of ¥109.99.
GuruFocus considers iRay Group to be Modestly Undervalued.
Key valuation signals for SHSE:688301:
EBITDA Margin %: 31.89% (near median its 10-year median of 34.55)
GF Value™: ¥109.99 vs. price of ¥88.54 (19.5% below fair value)
Industry Position: 299.6% above the Medical Devices & Instruments median (#76 of 814)
No single metric tells the full story. See the SHSE:688301 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688301 has been successfully added to your 
